Ascent Wealth Partners LLC grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,009 shares of the company’s stock after purchasing an additional 119 shares during the quarter. Ascent Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $3,095,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the business. Inscription Capital LLC grew its position in shares of Eli Lilly and Company by 1.0% in the third quarter. Inscription Capital LLC now owns 1,222 shares of the company’s stock valued at $1,083,000 after purchasing an additional 12 shares during the last quarter. Garner Asset Management Corp lifted its stake in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock valued at $411,000 after buying an additional 12 shares during the period. Boston Financial Mangement LLC lifted its stake in shares of Eli Lilly and Company by 0.3% during the third quarter. Boston Financial Mangement LLC now owns 5,020 shares of the company’s stock valued at $4,447,000 after buying an additional 13 shares during the period. Key Financial Inc lifted its stake in shares of Eli Lilly and Company by 1.5% during the third quarter. Key Financial Inc now owns 883 shares of the company’s stock valued at $782,000 after buying an additional 13 shares during the period. Finally, Shoker Investment Counsel Inc. lifted its stake in shares of Eli Lilly and Company by 2.0% during the third quarter. Shoker Investment Counsel Inc. now owns 679 shares of the company’s stock valued at $602,000 after buying an additional 13 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Price Performance
LLY opened at $874.12 on Friday. The company has a 50-day moving average of $801.33 and a 200-day moving average of $847.13. The company has a market capitalization of $828.82 billion, a P/E ratio of 74.65, a PEG ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.
Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
Eli Lilly and Company Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 51.24%.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on LLY shares. Bank of America reissued a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Finally, Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,000.28.
View Our Latest Research Report on LLY
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- What Are Earnings Reports?
- These 5 Energy Stocks Hedge Inflation With Growth Potential
- Trading Stocks: RSI and Why it’s Useful
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- DuPont’s Electronics Spinoff: The Start of Something Big
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.